Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Poniard Pharmaceuticals has selected AltheaDx's Express Pathway program to identify molecular signatures which may be correlated to platinum resistance.
Subscribe to our email newsletter
Picoplatin, Poniard’s lead product candidate, is a new generation platinum agent designed to overcome platinum resistance. The development of molecular signatures of platinum resistance may allow the prediction of clinical response to picoplatin treatment and may improve outcomes for patients with platinum-resistant cancers.
Jerry McMahon, chairman and CEO of Poniard, said: “AltheaDx’s high throughput gene expression platform facilitates the identification of molecular signature of platinum resistance that can guide therapeutic choices.”